Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial
- 1 July 2000
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 11 (7) , 799-805
- https://doi.org/10.1023/a:1008389402580
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of LifeJournal of Clinical Oncology, 1999
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II studyAnnals of Oncology, 1997
- Revisions in the International System for Staging Lung CancerChest, 1997
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Phase II Study of Taxol, Merbarone, and Piroxantrone in Stage IV Non-Small-Cell Lung Cancer: The Eastern Cooperative Oncology Group ResultsJNCI Journal of the National Cancer Institute, 1993
- Taxol: Twenty Years Later, the Story UnfoldsJNCI Journal of the National Cancer Institute, 1991
- Sequences of taxol and cisplatin: a phase I and pharmacologic study.Journal of Clinical Oncology, 1991
- Exact Inference for Contingency Tables with Ordered CategoriesJournal of the American Statistical Association, 1990
- Asymptotically Efficient Rank Invariant Test ProceduresJournal of the Royal Statistical Society. Series A (General), 1972